Beltran Lab

You are here

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

TitleNeuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Publication TypeJournal Article
Year of Publication2018
AuthorsPuca L, Vlachostergios PJ, Beltran H
JournalCold Spring Harb Perspect Med
Date Published2018 May 29
ISSN2157-1422
Abstract

Although a de novo clinical presentation of small cell neuroendocrine carcinoma of the prostate is rare, a subset of patients previously diagnosed with prostate adenocarcinoma may develop neuroendocrine features in later stages of castration-resistant prostate cancer (CRPC) progression as a result of treatment resistance. Despite sharing clinical, histologic, and some molecular features with other neuroendocrine carcinomas, including small cell lung cancer, castration-resistant neuroendocrine prostate cancer (CRPC-NE) is clonally derived from prostate adenocarcinoma. CRPC-NE therefore retains early prostate cancer genomic alterations and acquires new molecular changes making them resistant to traditional CRPC therapies. This review focuses on recent advances in our understanding of CRPC-NE biology, the transdifferentiation/plasticity process, and development and characterization of relevant CRPC-NE preclinical models.

DOI10.1101/cshperspect.a030593
Alternate JournalCold Spring Harb Perspect Med
PubMed ID29844220